{"nctId":"NCT01961349","briefTitle":"Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy","startDateStruct":{"date":"2013-10"},"conditions":["Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy"],"count":279,"armGroups":[{"label":"Group 1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Intralipid"]},{"label":"Group 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ICI35,868 (Diprivan)"]},{"label":"Group 3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ICI35,868 (Diprivan) + EES0000645/A (SDS)"]}],"interventions":[{"name":"Intralipid","otherNames":[]},{"name":"ICI35,868 (Diprivan)","otherNames":[]},{"name":"ICI35,868 (Diprivan) + EES0000645/A (SDS)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1.Provision of written informed consent prior to any study-related procedures/examinations 2.Aged 20 years and older 3.Subjects who are planned to undergo a non-emergent EGD or colonoscopy, including gastrointestinal endoscopic polypectomy that shall be completed within 1 hour (excluding the endoscopic submucosal dissection and ultrasonic endoscope, pernasal endoscope, etc.). Exclusion Criteria:\n\n1. involvement in the planning and/or conduct of the study (applies to both sponsor's employees and/or staffs at the study site)\n2. Subjects who underwent a endoscopic procedure under ICI35,868 (propofol) administration within 1 year.\n3. Participation in another clinical study with an investigational product within 4 weeks prior to randomisation.\n4. Baseline (Visit 1) of blood oxygen saturation (SpO2)\\<90% (room air)\n5. ASA III, IV, V and VI ; Subject with serious disease of cardiovascular, respiratory, renal, liver, pancreatic or endocrine function.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"PSSI Total Score","description":"PSSI (Statistics of Patient Satisfaction with Sedation Instrument) total score obtained from 20 questions (1 to 7 points for each) adjusted to have range of 0 ( very dissatisfied: all items scored with 1 point) to 100 (very satisfied: all items scored with 7 points)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":"19.7"},{"groupId":"OG001","value":"81.2","spread":"12.5"},{"groupId":"OG002","value":"80.8","spread":"14.1"}]}]}]},{"type":"PRIMARY","title":"Achivement of Target Sedation","description":"The target sedation is defined as MOAA/S (Modified Observer's Assessment of Alertness/Sedation) scores 2 to 4 for â‰¥50% of all MOAA/S measurements from scope-in to scope-out.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"88.1","spread":null},{"groupId":"OG002","value":"94.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Abdominal pain lower","blood urine present","disinhibition","sedation","oxygen saturation decreased"]}}}